Pliant Therapeutics, Inc. (PLRX)
NasdaqGS: PLRX
· 即時價格 · USD
1.17
+0.04 (3.54%)
收盤價： Sep 11, 2026, 3:59 PM
1.17
+0.00%
盤後: 7:30 PM
股價、關鍵數字和最新消息，都在這一頁。
Pliant Therapeutics, Inc.（PLRX）股價、分析與資料
3.54% (1D)
| 買價 | 0.84 |
| 市值 | 72.4M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -92.3M |
| 1.28 | |
| -1.5 | |
| n/a | |
| -0.91 | |
| P/B (ttm) | 0.49 |
| P/S (ttm) | 0.00 |
| 財報日期 | Nov 5, 2026 |
| 賣價 | 1.47 |
| 成交量 | 173,458 |
| 20 日平均成交量 | 498,159 |
| 開盤價 | 1.14 |
| 前收盤價 | 1.13 |
| 當日區間 | 1.14 - 1.18 |
| 52 週範圍 | 1.02 - 1.95 |
| 分析師 | 保持 |
| 目標價 | 2 (70.94%) |
| 股利 | n/a |
| 除息日 | n/a |
關於 PLRX
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integr...
完整的公司簡介財報驚奇
Pliant Therapeutics 已於 Aug 11, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.36 低於預期 -0.02, 年增 49.30% 成長.
